Literature DB >> 18790204

Optimal C2 concentration of cyclosporin corrected with good efficacy and safety in Asian kidney transplant recipients.

S M Wang1, M K Lai, S C Chueh, H C Tai, S D Chung.   

Abstract

INTRODUCTION: Calcineurin inhibitors (CNI) are known for their renal toxicity. Lower CNI exposure is a reasonable option to mitigate potential CNI-induced renal toxicity. Herein we have presented our long-term results after lower cyclosporine (CsA) exposure in the first year.
MATERIALS AND METHODS: Between 1997 and 2004, 63 renal transplant recipients received CsA-based immunosuppression. CsA dosing was adjusted according to the 2-hour whole blood concentration (C2) level. We retrospectively reviewed acute rejection and graft survivals rates, as well as whole blood C2 levels.
RESULTS: Review of serial mean C2 concentrations at 1, 2, 3, 6, and 12 months after transplantation were 1341, 1241, 1191, 1059, and 927 ng/mL, respectively. These levels were slightly lower than those suggested by the Consensus for C2 levels by Levy et al in 2002, namely, 1600 to 2000 ng/mL (mean, 1700); 1400 to 1600 ng/mL (mean, 1500); 1200 to 1400 ng/mL (mean, 1300); 1000 to 1200 ng/mL (mean, 1100), and 800 to 1000 ng/mL (mean, 900), respectively. Acute rejection rate at 3 months and 1 year are 17.5% and 23.8%. Graft survival at 1 year was 97% and at 5 years, 89%. Two patient were lost to fulminant hepatitis and acute myocardial infarction during the first year, which were not associated with underimmunosuppression.
CONCLUSION: Appropriate CsA C2 levels may be lower among Taiwanese. Our C2 dosing strategy resulted in good outcomes with acceptable side effects in our single-center experience. Appropriate CsA C2 levels for Asians deserve more attention in trials of larger scale; most reference levels are presently concluded from studies of Caucasians.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790204     DOI: 10.1016/j.transproceed.2008.06.030

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects.

Authors:  Yong Zeng; Yi-jing He; Fu-yuan He; Lan Fan; Hong-hao Zhou
Journal:  Acta Pharmacol Sin       Date:  2009-04       Impact factor: 6.150

2.  Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial.

Authors:  Takao Saito; Masayuki Iwano; Koichi Matsumoto; Tetsuya Mitarai; Hitoshi Yokoyama; Noriaki Yorioka; Shinichi Nishi; Ashio Yoshimura; Hiroshi Sato; Satoru Ogahara; Hideki Shuto; Yasufumi Kataoka; Shiro Ueda; Akio Koyama; Shoichi Maruyama; Masaomi Nangaku; Enyu Imai; Seiichi Matsuo; Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2013-12-23       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.